Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Antiplatelet therapy

Clopidogrel–PPI interaction, an ongoing controversy

Nature Reviews Cardiology volume 8, pages 7–8 (2011)Cite this article

Subjects

Although a diminished pharmacodynamic effect of clopidogrel has been demonstrated in patients treated with proton-pump inhibitors (PPIs), whether its clinical efficacy is reduced remains highly controversial. The FDA and European Medicines Agency recommend that PPIs and clopidogrel should not routinely be coadministered, and the 2010 expert consensus guidelines support this recommendation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Gurbel, P. A., Tantry, U. S. & Kereiakes, D. J. Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. Drug Healthcare and Patient Safety 2, 233–240 (2010).

    Article  CAS  Google Scholar 

  2. Furuta, T., Iwaki, T. & Umemura, K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br. J. Clin. Pharmacol. 70, 383–392 (2010).

    Article  CAS  Google Scholar 

  3. Bhatt, D. L. et al. Clopidogrel with or without omeprazole in coronary artery disease. N. Engl. J. Med. doi:10.1056/NEJMoa1007964.

    Article  CAS  Google Scholar 

  4. Charlot, M. et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann. Intern. Med. 153, 378–386 (2010).

    Article  Google Scholar 

  5. Kreutz, R. P. et al. Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel medco outcomes study. Pharmacotherapy 30, 787–796 (2010).

    Article  CAS  Google Scholar 

  6. Dunn, S. P. et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial [abstract 3999]. Circulation 118, S815 (2008).

    Google Scholar 

  7. US Department of Health & Human Services; FDA. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC) [online], (2009).

  8. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors [online], (2009).

  9. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation doi:10.1161/CIR.0b013e318202f701.

Download references

Author information

Authors and Affiliations

  1. Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Sinai Hospital of Baltimore, 2401 W. Belvedere Avenue, Baltimore, 21215, MD, USA

    Paul A. Gurbel & Udaya S. Tantry

Authors
  1. Paul A. Gurbel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Udaya S. Tantry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul A. Gurbel.

Ethics declarations

Competing interests

P. A. Gurbel has acted as a consultant for AstraZeneca, Daiichi Sankyo, and Pozen; he has received Speakers' Bureau honoraria from AstraZeneca and Daiichi Sankyo; and he has received research support from AstraZeneca, Bayer, Daiichi Sankyo, Eli Lilly, Portola Pharmaceuticals, Pozen, Sanofi-Aventis and Schering-Plough. U. S. Tantry declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gurbel, P., Tantry, U. Clopidogrel–PPI interaction, an ongoing controversy. Nat Rev Cardiol 8, 7–8 (2011). https://doi.org/10.1038/nrcardio.2010.185

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrcardio.2010.185

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing